Jul 18

Compare the Global Sales of Blockbuster Drugs Losing Patent this Year (2014)

Compare the global sales of 2013 and 2012 of the top ten blockbuster drugs which is losing patent this year. Teva Pharmaceutical’s Copaxone is the most affected drugs in terms of sales as the sales of 2013 has increased to 4.328 billions bearing the highest loss. Least affected Drug is AbbVie’s Trilipix which has faced the decrease in sales from¬†1.098 billions to 303 millions.

Blockbuster Drugs Global Sales 2012-13
Blockbuster Drugs Global Sales 2012-13

 

Table: Global Sales of Blockbuster Drugs for 2012 and 2013

Brand NameGlobal Sales 2012 USD (b)Global Sales 2013

USD (b)

Copaxone3.9964.328
Nexium3.9943.872
Micardis/Micardis HCT2.2170.97
Sandostatin LAR1.5121.589
Exforge/Exforge HCT1.3521.456
Nasonex1.2681.335
Trilipix1.0980.303
Evista1.011.05
Renagel/Renvela0.8610.75
Restasis0.7920.94

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.